Cingulate Inc. (CINGW) Stock Price & Analysis

Cingulate Inc. (CINGW) Healthcare & Pipeline Overview

Cingulate Inc. is a clinical-stage biopharmaceutical company specializing in treatments for central nervous system disorders, particularly ADHD, with lead candidates CTx-1301 and CTx-1302. The company aims to address unmet needs in neurobiological disorders, positioning itself within the competitive biotechnology landscape.

What Is the Investment Thesis for CINGW?

Cingulate Inc. presents a high-risk, high-reward investment opportunity given its clinical-stage status and focus on CNS disorders. The success of its lead product candidates, CTx-1301 and CTx-1302, in clinical trials is crucial for future growth. Positive clinical data could significantly increase the company's valuation. The company's ability to secure partnerships and funding will be essential for advancing its pipeline. The current market capitalization of $0.00B reflects the speculative nature of the investment, with a P/E ratio of -2.14, indicating a lack of current profitability. Investors should closely monitor clinical trial results and regulatory developments.

Based on FMP financials and quantitative analysis

CINGW Key Highlights

Cingulate Inc. is a clinical-stage biopharmaceutical company focused on central nervous system disorders.

• Lead product candidates CTx-1301 and CTx-1302 target the treatment of attention deficit/hyperactivity disorder (ADHD).
• Developing CTx-2103 for the treatment of anxiety disorders, expanding its therapeutic pipeline.
• The company was founded in 2012 and is headquartered in Kansas City, Kansas, with an additional location in Morristown, New Jersey.
• Market capitalization of $0.00B reflects its early stage and speculative nature.

Who Are CINGW's Competitors?

CINGW is benchmarked below against 8 industry peers on price, market cap, and our AI MoonshotScore.

AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance

What Are CINGW's Key Strengths?

Focus on unmet needs in CNS disorders

• Proprietary drug formulations
• Experienced management team
• Pipeline of product candidates in clinical development

What Are CINGW's Weaknesses?

Clinical-stage company with no approved products

• Limited financial resources
• Dependence on successful clinical trial outcomes
• High risk of regulatory setbacks

What Are the Key Risks for CINGW?

Financial-distress signal — its Altman Z-Score of -6.14 sits in the distress zone (elevated bankruptcy risk).

• Inconsistent delivery — missed Wall Street EPS estimates in 6 of the last 8 reported quarters.
• Weak fundamentals — a Piotroski F-Score of 2/9 flags soft profitability, leverage or efficiency.
• Failure to achieve positive clinical trial results for its product candidates.
• Regulatory setbacks and delays in FDA approval process.
• Competition from established pharmaceutical companies with approved ADHD and anxiety treatments.
• Dependence on securing additional funding to support clinical development.
• Intellectual property challenges and patent disputes.

What Are CINGW's Competitive Advantages?

• Proprietary drug formulations (CTx-1301, CTx-1302, CTx-2103)
• Patent protection on its product candidates
• Clinical data supporting the efficacy and safety of its products
• Expertise in developing treatments for CNS disorders

What Does CINGW Do?

Founded in 2012, Cingulate Inc. is a clinical-stage biopharmaceutical company dedicated to developing innovative treatments for central nervous system (CNS) and neurobiological disorders. The company's primary focus is on addressing the unmet needs in the treatment of attention deficit/hyperactivity disorder (ADHD) and anxiety disorders. Cingulate's lead product candidates include CTx-1301 (dexmethylphenidate) and CTx-1302 (dextroamphetamine), both designed for the treatment of ADHD. These product candidates are formulated to provide a differentiated approach to managing ADHD symptoms. Additionally, Cingulate is developing CTx-2103 for the treatment of anxiety disorders, further expanding its pipeline of CNS-focused therapeutics. Headquartered in Kansas City, Kansas, with an additional location in Morristown, New Jersey, Cingulate is working to advance its clinical programs and bring novel therapies to patients. The company operates with a team of 13 employees under the leadership of CEO Shane J. Schaffer.

What Products and Services Does CINGW Offer?

• Develops product candidates for central nervous system (CNS) disorders.
• Focuses on treatments for attention deficit/hyperactivity disorder (ADHD).
• Develops treatments for anxiety disorders.
• Conducts clinical trials to evaluate the safety and efficacy of its product candidates.
• Seeks regulatory approval from the FDA for its product candidates.
• Aims to commercialize its approved products and make them available to patients.

How Does CINGW Make Money?

• Develops and patents novel pharmaceutical products.
• Conducts clinical trials to demonstrate efficacy and safety.
• Seeks regulatory approval for commercialization.
• Out-licenses or commercializes approved products directly.

What Industry Does CINGW Operate In?

The biotechnology industry is characterized by high risk and high reward, with companies like Cingulate focusing on developing novel therapies for unmet medical needs. The ADHD and anxiety disorders market is substantial, with a growing prevalence and demand for effective treatments. Competition includes established pharmaceutical companies and other emerging biotechs. Cingulate's success depends on its ability to navigate the complex regulatory landscape, secure funding, and demonstrate clinical efficacy. The industry is driven by innovation, with companies constantly seeking to develop improved treatments and address unmet needs.

Who Are CINGW's Key Customers?

• Patients with ADHD
• Patients with anxiety disorders
• Healthcare providers who prescribe medications for CNS disorders
• Pharmacies that dispense medications

Insider Activity

14 transactions · 0 purchases, 0 sales, 14 other transactions · 8 identified insiders · of the newest 100 records, those within the last 180 days, newest dated Jul 16, 2026. Purchases and sales use the reported transaction category. Other transactions include awards, exercises, gifts, withholding and unclassified activity; an acquisition or disposition alone is not a purchase or sale. These records do not establish intent.

Wall Street analysts project Cingulate Inc. revenue of about $2.9M for fiscal 2026, with EPS near $-2.13. The estimate reflects 5 contributing analysts.

Cingulate Inc. has missed Wall Street's EPS estimate in 6 of its last 8 reported quarters — a mixed record worth weighing. Reported results have landed about 24.5% below estimates on average.

Cingulate Inc.'s Piotroski F-Score is 2/9, a 9-point checklist of profitability, leverage and efficiency — flagging fundamental weakness worth scrutiny. Its Altman Z-Score of -6.14 places it in the distress zone, a signal of elevated financial risk.

Key Financial Metrics

Return on assets is -87.1%, showing how much profit it generates from its asset base. Its free cash flow yield is -33.5%, a gauge of the cash the business throws off relative to its market value. A current ratio of 3.50 indicates the company holds enough short-term assets to cover its near-term obligations. Its earnings yield is -114.3%, the inverse of the P/E and a quick read on earnings relative to price.

Company Profile

Cingulate Inc. operates in the Biotechnology industry within the Healthcare sector. It is headquartered in Kansas City, US. The company is led by CEO Shane J. Schaffer. CINGW has traded publicly since 2021.

CINGW Financials

CINGW Latest News

CINGW Analyst Consensus

CINGW MoonshotScore

Common Questions About CINGW (Healthcare)

Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.

Official Resources